Immuno-Oncology | Specialty

Adjuvant Imatinib for Gastrointestinal Stromal Tumor

October 9th 2015

Risk Stratification and Prognostic Factors in GIST

October 9th 2015

Gastrointestinal Stromal Tumor Diagnosis

October 9th 2015

Medication, Imaging, and Surgery Advancements for GIST

October 9th 2015

Evolving Understanding of Gastrointestinal Stromal Tumors

October 9th 2015

FDA Expands Nivolumab Lung Cancer Approval

October 9th 2015

Acting 3 months ahead of schedule, the FDA approved nivolumab for patients with nonsquamous non–small cell lung cancer previously treated with platinum-based chemotherapy.

PD-L1 Inhibitor Avelumab May Improve Survival in Metastatic Urothelial Carcinoma

October 7th 2015

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Pembrolizumab, Avelumab Show Promise in Merkel Cell Carcinoma

October 7th 2015

Encouraging findings and regulatory milestones have recently been announced for the PD-1 inhibitor pembrolizumab and the PD-L1 inhibitor avelumab as treatments for patients with metastatic Merkel cell carcinoma.

Checkpoint Inhibition Continues Rapid Advance in Non-Small Cell Lung Cancer

October 6th 2015

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

Dr. David Ettinger Discusses the Road Ahead for Immunotherapy in NSCLC

October 6th 2015

David S. Ettinger, MD, discusses recent advancements in NSCLC, specifically with immunotherapy, and explains challenges that have stemmed from these developments.

Dr. Andrea Apolo on Treatment Challenges in Metastatic Bladder Cancer

October 2nd 2015

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

FDA Approves Pembrolizumab for PD-L1-Positive Lung Cancer

October 2nd 2015

The FDA approved pembrolizumab (Keytruda) as a treatment for patients with pretreated advanced non­–small cell lung cancer across all histologies whose tumors express PD-L1.

FDA Schedules Advisory Meeting for MCNA in Bladder Cancer

October 2nd 2015

The FDA has scheduled an advisory hearing to discuss the biologics license application for the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guérin therapy.

FDA Approves Nivolumab/Ipilimumab Combination for BRAF Wild-Type Melanoma

October 1st 2015

The FDA has granted an accelerated approval to the combination of nivolumab and ipilimumab as a treatment for patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Research Leader Discusses FDA-Funded Immunotherapy for Head and Neck Cancer

September 29th 2015

Brett Miles, MD, DDS, discusses the potential of ADXS11-001 in HPV-associated head and neck cancer and other emerging therapies and treatment strategies.

Longer Follow-up Confirms Nivolumab OS Benefit in Nonsquamous NSCLC

September 28th 2015

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

T-VEC/Pembrolizumab Combination Demonstrates Safety in Melanoma

September 27th 2015

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

Atezolizumab Provides Viable Treatment Option in Metastatic Urothelial Carcinoma

September 27th 2015

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

Two Pivotal Studies Show Efficacy of Atezolizumab in PD-L1-Positive NSCLC

September 27th 2015

Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.

Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma

September 27th 2015

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).